Cardiol Therapeutics Inc Class A (CRDL NASDAQ) stock market data APIs
$1.1191
-0.02(-1.8%)
as of October 31, 2025
Try our APIs with
free plan!
Cardiol Therapeutics Inc Class A Financial Data Overview
Price chart is built with
Anychart
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Prev. Close
1.1191
Open
1.1002
High
1.1191
Low
1.0997
52 wk Range
0.7709-2.24
Market Cap
107 M
Shares Outstanding
95 129 K
EPS
-0.0722
Beta
0.619
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cardiol Therapeutics Inc Class A data using free add-ons & libraries
Get Cardiol Therapeutics Inc Class A Fundamental Data
Cardiol Therapeutics Inc Class A Fundamental data includes:
- Net Revenue:
- EBITDA: -40 178 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-19
- EPS/Forecast: -0.0997
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cardiol Therapeutics Inc Class A News
New
5 Under-the-Radar Biotech Stocks That Could Soar in 2026
The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the next wave of breakthroughs may come from companies flying well below Wall Str...
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
For Immediate Release Chicago, IL – October 15, 2025 – Today, Zacks Equity Research discusses Akebia Therapeutics AKBA, Ironwood Pharmaceuticals IRWD, Pyxis Oncology PYXS, Cardiol Therapeutics CR...
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark drug-prici...
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Confer...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
